S&P 500   2,987.98 (+0.74%)
DOW   26,991.96 (+0.76%)
QQQ   192.62 (+0.80%)
AAPL   236.87 (+0.42%)
FB   188.14 (+2.65%)
MSFT   141.02 (+1.05%)
GOOGL   1,231.89 (+1.16%)
AMZN   1,745.48 (+0.52%)
CGC   20.17 (+6.95%)
NVDA   193.25 (+3.60%)
MU   45.58 (+1.60%)
BABA   174.47 (+1.93%)
GE   8.70 (-0.23%)
TSLA   257.60 (+0.25%)
AMD   30.56 (+0.10%)
F   8.96 (+1.59%)
ACB   3.78 (+7.69%)
PRI   122.44 (+0.80%)
NFLX   283.45 (-0.73%)
BAC   29.43 (+1.00%)
GILD   65.13 (+0.95%)
DIS   129.71 (+0.01%)
S&P 500   2,987.98 (+0.74%)
DOW   26,991.96 (+0.76%)
QQQ   192.62 (+0.80%)
AAPL   236.87 (+0.42%)
FB   188.14 (+2.65%)
MSFT   141.02 (+1.05%)
GOOGL   1,231.89 (+1.16%)
AMZN   1,745.48 (+0.52%)
CGC   20.17 (+6.95%)
NVDA   193.25 (+3.60%)
MU   45.58 (+1.60%)
BABA   174.47 (+1.93%)
GE   8.70 (-0.23%)
TSLA   257.60 (+0.25%)
AMD   30.56 (+0.10%)
F   8.96 (+1.59%)
ACB   3.78 (+7.69%)
PRI   122.44 (+0.80%)
NFLX   283.45 (-0.73%)
BAC   29.43 (+1.00%)
GILD   65.13 (+0.95%)
DIS   129.71 (+0.01%)
Log in

AtriCure Stock Price, News & Analysis (NASDAQ:ATRC)

$26.20
+0.44 (+1.71 %)
(As of 10/15/2019 10:32 AM ET)
Today's Range
$25.86
Now: $26.20
$26.20
50-Day Range
$23.75
MA: $25.50
$27.50
52-Week Range
$22.57
Now: $26.20
$34.39
Volume25,781 shs
Average Volume233,991 shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.3
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$201.63 million
Book Value$6.47 per share

Profitability

Net Income$-21,140,000.00

Miscellaneous

Employees620
Market Cap$1.02 billion
Next Earnings Date10/30/2019 (Confirmed)
OptionableOptionable

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.


AtriCure (NASDAQ:ATRC) Frequently Asked Questions

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure Inc. (NASDAQ:ATRC) announced its quarterly earnings results on Tuesday, July, 30th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. The medical device company earned $58.90 million during the quarter, compared to the consensus estimate of $57.76 million. AtriCure had a negative return on equity of 13.06% and a negative net margin of 9.46%. The company's quarterly revenue was up 13.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.19) EPS. View AtriCure's Earnings History.

When is AtriCure's next earnings date?

AtriCure is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for AtriCure.

How can I listen to AtriCure's earnings call?

AtriCure will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its FY 2019 earnings guidance on Monday, August, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $224.5-228.5 million, compared to the consensus revenue estimate of $227.06 million.

What price target have analysts set for ATRC?

5 analysts have issued 1 year price objectives for AtriCure's shares. Their predictions range from $30.00 to $40.00. On average, they expect AtriCure's share price to reach $36.20 in the next year. This suggests a possible upside of 38.2% from the stock's current price. View Analyst Price Targets for AtriCure.

What is the consensus analysts' recommendation for AtriCure?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AtriCure.

Has AtriCure been receiving favorable news coverage?

Headlines about ATRC stock have trended somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AtriCure earned a news impact score of 1.4 on InfoTrie's scale. They also gave news stories about the medical device company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for AtriCure.

Are investors shorting AtriCure?

AtriCure saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,180,000 shares, a drop of 6.3% from the August 30th total of 1,260,000 shares. Based on an average trading volume of 260,700 shares, the short-interest ratio is presently 4.5 days. Currently, 3.1% of the company's stock are sold short. View AtriCure's Current Options Chain.

Who are some of AtriCure's key competitors?

What other stocks do shareholders of AtriCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include Amgen (AMGN), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), AbbVie (ABBV), Micron Technology (MU), bluebird bio (BLUE), Cellectis (CLLS), Exelixis (EXEL), Galectin Therapeutics (GALT) and Heron Therapeutics (HRTX).

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:
  • Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)
  • Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 53)
  • Mr. Salvatore Privitera, Chief Technology Officer (Age 52)
  • Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41)

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $26.20.

How big of a company is AtriCure?

AtriCure has a market capitalization of $1.02 billion and generates $201.63 million in revenue each year. The medical device company earns $-21,140,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. AtriCure employs 620 workers across the globe.View Additional Information About AtriCure.

What is AtriCure's official website?

The official website for AtriCure is http://www.atricure.com/.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.


MarketBeat Community Rating for AtriCure (NASDAQ ATRC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  412 (Vote Outperform)
Underperform Votes:  296 (Vote Underperform)
Total Votes:  708
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel